| HUMAN-TRIAL | evidence | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Zepbound | Liver health · human-rct · n = 204 | — |
| HUMAN-TRIAL | evidence | Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Mounjaro | human-rct · n = 120 | — |
| REGULATORY | regulatory | Zepbound — FDA prescribing information | FDA | — | 2026-04-22 |
| REGULATORY | regulatory | Mounjaro — FDA prescribing information | FDA | — | 2026-04-22 |
| REGULATORY | regulatory | D-0394-2026 — Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03. | FDA | — | 2026-02-26 |
| REGULATORY | regulatory | D-0395-2026 — Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04. | FDA | — | 2026-02-26 |
| REGULATORY | regulatory | D-0120-2026 — Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0092-2026 — Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Extension Health and Synergy Wellness 60mg, 10mL vial lyophilized. | FDA | — | 2025-07-30 |
| REGULATORY | regulatory | D-0554-2025 — Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0558-2025 — Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0557-2025 — Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0555-2025 — Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0559-2025 — Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0560-2025 — Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0556-2025 — Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0482-2025 — Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0486-2025 — Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0485-2025 — Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0484-2025 — Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0483-2025 — Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0655-2024 — TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0656-2024 — TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0651-2024 — Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0511-2024 — Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77018, internally assigned NDC 99000-9278-64 | FDA | — | 2024-04-20 |
| REGULATORY | regulatory | ZEPBOUND — FDA application NDA217806 | FDA | — | 2023-11-08 |
| REGULATORY | regulatory | D-0771-2023 — Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, NDC: 99000-9278-64. | FDA | — | 2023-05-11 |
| REGULATORY | regulatory | MOUNJARO — FDA application NDA215866 | FDA | — | 2022-05-13 |
| ANIMAL | evidence | Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-kappaB signaling pathway. | Tirzepatide | animal | 2026-10-01 |
| ANIMAL | evidence | Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD + homeostasis and enhancing Pink1-Parkin-mediated mitophagy. | Tirzepatide | Inflammation · animal | 2026-08-01 |
| ANIMAL | evidence | Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. | Tirzepatide | Cognition & memory · animal | 2026-07-21 |
| ANIMAL | evidence | Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin. | Tirzepatide | Glycemic control · animal | 2026-07-01 |
| ANIMAL | evidence | Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine. | Tirzepatide | Gut barrier & GI healing · animal | 2026-06-17 |
| ANIMAL | evidence | Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats. | Tirzepatide | Lipid & cardiovascular markers · animal | 2026-06-01 |
| ANIMAL | evidence | Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution. | Tirzepatide | Gut barrier & GI healing · animal | 2026-05-28 |
| ANIMAL | evidence | Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. | Tirzepatide | Glycemic control · animal | 2026-04-07 |
| ANIMAL | evidence | Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. | Tirzepatide | Weight & fat loss · animal | 2026-04-01 |
| ANIMAL | evidence | Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration. | Tirzepatide | Lipid & cardiovascular markers · animal | 2026-04-01 |
| ANIMAL | evidence | Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents. | Tirzepatide | animal | 2026-04-01 |
| ANIMAL | evidence | Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice. | Tirzepatide | animal | 2026-04-01 |
| ANIMAL | evidence | Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation. | Tirzepatide | Inflammation · animal | 2026-03-01 |
| ANIMAL | evidence | Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway. | Tirzepatide | Weight & fat loss · animal | 2026-02-10 |
| ANIMAL | evidence | Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. | Tirzepatide | Gut barrier & GI healing · animal | 2026-02-01 |
| ANIMAL | evidence | Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target. | Tirzepatide | Weight & fat loss · animal | 2026-02-01 |
| ANIMAL | evidence | A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. | Tirzepatide | Weight & fat loss · animal | 2026-02-01 |
| ANIMAL | evidence | Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction. | Tirzepatide | animal | 2026-02-01 |
| ANIMAL | evidence | Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice. | Tirzepatide | animal | 2026-02-01 |
| ANIMAL | evidence | The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model. | Tirzepatide | Gut barrier & GI healing · animal | 2026-01-01 |
| ANIMAL | evidence | Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study. | Tirzepatide | animal | 2026-01-01 |
| ANIMAL | evidence | A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity. | Tirzepatide | Weight & fat loss · animal | 2026-01-01 |
| ANIMAL | evidence | Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on beta-Cell Identity in db/db Mice. | Tirzepatide | Glycemic control · animal | 2026-01-01 |